Neferine, an Alkaloid from Lotus Seed Embryos, Exerts Antiseizure and Neuroprotective Effects in a Kainic Acid-Induced Seizure Model in Rats
Overview
Chemistry
Molecular Biology
Affiliations
Current anti-seizure drugs fail to control approximately 30% of epilepsies. Therefore, there is a need to develop more effective anti-seizure drugs, and medicinal plants provide an attractive source for new compounds. This study aimed to evaluate the possible anti-seizure and neuroprotective effects of neferine, an alkaloid from the lotus seed embryos of , in a kainic acid (KA)-induced seizure rat model and its underlying mechanisms. Rats were intraperitoneally (i.p.) administrated neferine (10 and 50 mg/kg) 30 min before KA injection (15 mg/kg, i.p.). Neferine pretreatment increased seizure latency and reduced seizure scores, prevented glutamate elevation and neuronal loss, and increased presynaptic protein synaptophysin and postsynaptic density protein 95 expression in the hippocampi of rats with KA. Neferine pretreatment also decreased glial cell activation and proinflammatory cytokine (interleukin-1β, interleukin-6, tumor necrosis factor-α) expression in the hippocampi of rats with KA. In addition, NOD-like receptor 3 (NLRP3) inflammasome, caspase-1, and interleukin-18 expression levels were decreased in the hippocampi of seizure rats pretreated with neferine. These results indicated that neferine reduced seizure severity, exerted neuroprotective effects, and ameliorated neuroinflammation in the hippocampi of KA-treated rats, possibly by inhibiting NLRP3 inflammasome activation and decreasing inflammatory cytokine secretion. Our findings highlight the potential of neferine as a therapeutic option in the treatment of epilepsy.
Neuroprotective effects of pink lotus oil in kainic acid-induced epilepsy.
Kongsui R, Chanmanee T, Promsrisuk T, Klimaschewski L, Sriraksa N, Jittiwat J Heliyon. 2024; 10(18):e38070.
PMID: 39381248 PMC: 11458948. DOI: 10.1016/j.heliyon.2024.e38070.
Harnessing the power of natural alkaloids: the emergent role in epilepsy therapy.
Li S, Lin X, Duan L Front Pharmacol. 2024; 15:1418555.
PMID: 38962319 PMC: 11220463. DOI: 10.3389/fphar.2024.1418555.
NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development.
Haque I, Thapa P, Burns D, Zhou J, Sharma M, Sharma R Int J Mol Sci. 2024; 25(11).
PMID: 38892264 PMC: 11172514. DOI: 10.3390/ijms25116078.
Waris A, Ullah A, Asim M, Ullah R, Rajdoula M, Bello S Front Pharmacol. 2024; 15:1403232.
PMID: 38855752 PMC: 11160429. DOI: 10.3389/fphar.2024.1403232.
Role of NLRP3 inflammasome in central nervous system diseases.
Zhang L, Tang Y, Huang P, Luo S, She Z, Peng H Cell Biosci. 2024; 14(1):75.
PMID: 38849934 PMC: 11162045. DOI: 10.1186/s13578-024-01256-y.